Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Cancer Grand Challenges Conference: extrachromosomal DNA

This inaugural Cancer Grand Challenges Conference aims to unite a diverse range of researchers—from laboratory scientists to clinical practitioners, both within and beyond the extrachromosomal [...]

Go to Top